Non-peptide

NNMT inhibitor class (beyond 5-Amino-1MQ)

Also known as

NNMT inhibitors · 1MQ analogs · 5-Amino-1MQ analogs · NNMTi class · JBSNF-000088 · 6-methoxynicotinamide · JBSNF-000028 · JBSNF-000265 · MQ-scaffold NNMT inhibitors · 7-amino-1MQ · 2,3-diamino-1MQ · 1-methylquinolinium analogs · nicotinamide N-methyltransferase inhibitors · NAM-competitive NNMT inhibitors · tricyclic NNMT inhibitors (Sanofi series)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	A family of small-molecule NNMT inhibitors studied for fat metabolism; JBSNF-000088 and JBSNF-000028 are different molecules from 5-Amino-1MQ.
Why people look it up	Fat loss, body recomposition and NAD metabolism. Most human experience in these records concerns parent 5-Amino-1MQ, not the alternate inhibitors.

Notes

NNMT inhibitors are a family of research compounds people discuss for fat loss, body recomposition and NAD metabolism. Beyond 5-Amino-1MQ, names such as JBSNF-000088 and JBSNF-000028 mostly come from laboratory research. Parent-compound experiences and blend labels do not establish what a different inhibitor will do in a person.

A shared enzyme target, several different molecules. NNMT uses nicotinamide and a methyl donor, SAM, to make 1-methylnicotinamide. Inhibitors interrupt that reaction. JBSNF-000088 is 6-methoxynicotinamide; JBSNF-000028 is a tricyclic molecule. JBSNF-000265, 7-amino-1MQ and 2,3-diamino-1MQ are additional research identities, not interchangeable versions of one capsule. Kannt et al. 2018 — JBSNF-000088 metabolic study (Animal context · Accessed 2026-09-30) · Ruf et al. 2022 — tricyclic JBSNF-000028 study (Animal context · Accessed 2026-09-30)

Research excitement is different from a completed analog diary. A MuscleChemistry post retells mouse results and mentions unspecified human anecdotes. It supplies no named alternate-inhibitor human log. The JBSNF blend question likewise remains a question; a laboratory name on a label is not proof of a better human outcome. MuscleChemistry: Nicotinamide N-Methyltransferase (Secondhand community claim · Accessed 2026-09-30) · Evolutionary: 5-Amino-1MQ, NMN, JBSNF (Community discussion · Accessed 2026-09-30)

Source context — Kannt et al. 2018 — JBSNF-000088 metabolic study: Cell/animal study; 50 mg/kg twice-daily mouse exposure differs from a blend capsule label and supplies no human PK or dose. Industry-employed authors disclosed.

Source context — Ruf et al. 2022 — tricyclic JBSNF-000028 study: Mouse PK and laboratory screening, no human interaction test. Nature direct access redirected unsuccessfully; PMC browser extraction hit reCAPTCHA; Europe PMC fullTextXML was inspected.

Source context — MuscleChemistry: Nicotinamide N-Methyltransferase: Secondhand summary of mouse work, with unspecified anecdotes. No original human dose or verified analog log; copied study percentages are not human results.

Source context — Evolutionary: 5-Amino-1MQ, NMN, JBSNF: Blend composition is an unverified label repeated by the questioner; no frequency or completed JBSNF results. Commercial promotion appears in forum signatures. Mouse material repeated in post 1 remains animal-derived.

What people notice

Parent experiences	Some parent users report more energy or easier dieting, often with little stimulant buzz or appetite change. These are not demonstrated effects of JBSNF compounds.
Mixed results	Other parent users report only a small energy lift, no fat-loss benefit, or no results after six weeks. Named alternate-inhibitor diaries are not established here.

Notes

Energy, training and body recomposition. Parent users seek easier fat loss while maintaining training. In the May thread, one person describes 1 mg SubQ alongside retatrutide for energy without caffeine-like jumpiness. That experience does not establish a JBSNF benefit or a measured increase in metabolic rate. Reddit: 5-Amino-1MQ is this true? (Community discussion · Accessed 2026-09-30)

Little buzz and relatively unchanged appetite in original parent accounts. Those discussions contrast the parent with GLP-1 appetite suppression. Warmth or alertness also appears, but neither sensation measures fat oxidation or establishes how a different inhibitor feels.

Energy does not necessarily mean fat loss. Theappache10 described only a small energy benefit from injectable parent, without the hoped-for fat burning. Dull_Secretary_6734 felt energized after two weeks alongside retatrutide, but had not yet seen other benefits. Neither account isolates NNMT inhibition from the product or stack. Reddit: Looking for real-world experiences and data on 5-Amino-1MQ (Community discussion · Accessed 2026-09-30)

No response is not automatically a dosing mistake. ReasonEffective7123 reported no results after two weeks at 50 mg and four at 100 mg. Replies blamed dose; that explanation remains unproven. Reddit: 5 amino 1mq — best fat loss agent? (Community discussion · Accessed 2026-09-30)

Source context — Reddit: 5-Amino-1MQ is this true?: Parent only; multi-compound stacks. No verified human PK. Assertions about effective doses, oral conversion and claimed professional credentials are not validation.

Source context — Reddit: Looking for real-world experiences and data on 5-Amino-1MQ: Parent only; product identity, color and co-use unverified. Theappache10 gives route and amounts but no frequency. Earlier find calls missed comments; final Comments Section extraction exposed actual bodies.

Source context — Reddit: 5 amino 1mq — best fat loss agent?: Parent only; self-reported scans with a longer interval than use, no independent verification; liquid concentration absent. Replies advocating escalation do not establish a cause for nonresponse. Deleted and collapsed comments remain unavailable.

Doses people talk about

One oral blend label	50 mg parent 5-Amino-1MQ + 50 mg NMN + 5 mg JBSNF-000088 per capsule. The questioner gives no frequency or completed result; 5 mg is not an established standalone analog amount.
Parent oral reports	50–150 mg total/day, including 50 mg/day split into two 25 mg amounts. Competing lower and higher charts remain parent claims, not analog amounts.
Parent injections	One report gives 500 mcg–1.5 mg under the skin, frequency unstated; another gives 5 mg/day as two 2.5 mg injections. These cannot supply an oral or analog conversion.

Notes

One blend label: 50 mg parent, 50 mg NMN, 5 mg JBSNF-000088 per capsule. An Evolutionary forum poster asks about this oral combination. Frequency and completed results are absent; the 5 mg component is not an established standalone human dose. Evolutionary: 5-Amino-1MQ, NMN, JBSNF (Community discussion · Accessed 2026-09-30)

Parent oral reports: 50–150 mg total per day. Examples include 50 mg/day as two 25 mg doses, or 150 mg/day as 100 mg morning plus 50 mg midday. Separate original charts claim 5–25 mg/day, 100–300 mg/day or more, and mouse-derived 400–600 mg/day. These do not establish analog doses. Reddit: Experience with 5-Amino-1MQ after a month (Community discussion · Accessed 2026-09-30) · Reddit: 5 amino 1mq — best fat loss agent? (Community discussion · Accessed 2026-09-30)

Injected parent reports differ by orders of magnitude. Theappache10 reports 500 mcg–1.5 mg beneath the skin, with frequency unstated. Another thread includes 1 mg SubQ, 5 mg/day split into two 2.5 mg injections, and claims favoring much higher amounts. The original 150–500 mcg/day SC band remains a separate chart, not an oral conversion. Reddit: Looking for real-world experiences and data on 5-Amino-1MQ (Community discussion · Accessed 2026-09-30) · Reddit: 5-Amino-1MQ is this true? (Community discussion · Accessed 2026-09-30)

Source context — Reddit: Experience with 5-Amino-1MQ after a month: Parent only; unverified capsules/injections and stacks. Deficit and training confound effects. Emotional dulling is subjective. NADH blend frequency absent; injection recipe intentionally excluded.

Half-life, onset & duration

Felt onset	Parent accounts describe easier dieting at 2–3 weeks. No alternate-inhibitor onset is established.
Felt duration	The records do not establish how long one dose helps or how long an analog benefit persists after stopping.
Half-life	No measured human class value. In mice, JBSNF-000028 measured 2.36 hours by mouth and 1.77 into a vein; parent rat values were 6.90 hours by mouth and 3.80 into a vein. These are separate animal results.

Notes

Parent impressions at 2–3 weeks, or no benefit. The oral log describes easier dieting at 2–3 weeks; Naven71 noticed nothing after 30 days. Neither establishes another inhibitor's onset. Reddit: Experience with 5-Amino-1MQ after a month (Community discussion · Accessed 2026-09-30)

A reliable single-dose benefit window is unknown. Letsgobeachfun felt nothing by a second parent dose while also using SS-31, tirzepatide and GLOW. An early null cannot measure how long one dose acts; persistence after stopping a named analog is unestablished here. Reddit: Looking for real-world experiences and data on 5-Amino-1MQ (Community discussion · Accessed 2026-09-30)

No measured human clock for the class in these discussions. One parent user invokes a short half-life to justify split SubQ doses; another explicitly borrows 38% oral bioavailability from rodents. Neither supplies human clearance measurements. Borrowed animal or parent assumptions cannot set JBSNF timing. Half-life measures elimination, not how long energy or fat loss lasts. Reddit: 5-Amino-1MQ is this true? (Community discussion · Accessed 2026-09-30)

JBSNF-000028: mouse half-lives of 2.36 hours oral and 1.77 hours IV. Those measured means followed 10 mg/kg oral and 1 mg/kg IV. Its 50 mg/kg twice-daily efficacy design was separate. A screen found 90% MAO-A inhibition at 10 µM; this is molecule-specific laboratory activity, not a demonstrated human drug interaction. Ruf et al. 2022 — tricyclic JBSNF-000028 study (Animal context · Accessed 2026-09-30)

Parent rat half-lives: 6.90 hours oral, 3.80 hours IV. Awosemo's assay study reported 38.4% oral bioavailability in rats. These are parent-compound animal values, distinct from SC anecdotes, the JBSNF molecules and any human capsule exposure. Awosemo et al. 2021 — rat parent-compound pharmacokinetics (Animal context · Accessed 2026-09-30)

Source context — Awosemo et al. 2021 — rat parent-compound pharmacokinetics: Abstract only; rat parent assay. Administered doses and salt not specified in abstract; human and SC kinetics not measured.

Cycles people discuss

Parent blocks	4–6 weeks on with 2–4 off appears alongside 8–12-week charts and 4–6-week breaks. None establishes a human cycle for a named analog.

Notes

Parent blocks: 4–6 weeks or 8–12 weeks. DiscreetAcct4 describes 4–6 weeks on, 2–4 off: injected parent:NADH at 5:4, about 15 mg parent per administration, frequency unstated. Original charts instead include 8–12 weeks and 4–6-week breaks. No validated analog cycle follows. Reddit: Experience with 5-Amino-1MQ after a month (Community discussion · Accessed 2026-09-30)

Stacks

Parent combinations	Semaglutide, tirzepatide or retatrutide; MOTS-c; NMN or NR; sometimes GH-axis compounds. This discussion mostly concerns the parent product, with no established analog combination benefit.
Other cut stacks	SLU-PP-332, BAM15 and Cardarine-style compounds also appear beside NNMTi products. Their different targets do not establish that combining them works better.

Notes

Stacks make the supposed “next-generation” advantage difficult to judge. Original discussion pairs parent NNMTi with semaglutide, tirzepatide, retatrutide, MOTS-c and NMN or NR, sometimes adding GH-axis compounds. NMN/NR amounts around 250–500 mg/day and late-in-a-cut sequencing belong to stack-blog claims. They do not demonstrate an analog interaction, synergy or superiority.

Analog-specific stacks: Essentially none documented — people stack the parent product and only theorize about next-gen NNMTis. [community]

Other recomp RCs: SLU-PP-332 (exercise-mimetic; different target), BAM15 (mitochondrial uncoupler talk), cardarine-style — high confounders. [community] [anecdote]

Watch for

Reported parent symptoms	Emotional dulling, anxiety, disturbed sleep, nausea, loose stools, headache and fatigue. These reports do not establish an adverse-effect rate for the whole class.
Identity and units	An unknown analog, a seller label and the parent compound cannot share one chart. mg/mcg mistakes, uncertain contents and untested long-term effects remain concerns.

Notes

Parent symptoms include emotional dulling, anxiety and disrupted sleep. The oral log reports emotional dulling at week three; another thread reports anxiety and disturbed sleep. Original accounts also mention nausea, loose stools, headache and fatigue. None establishes a class adverse-effect rate. Reddit: Experience with 5-Amino-1MQ after a month (Community discussion · Accessed 2026-09-30) · Reddit: 5 amino 1mq — best fat loss agent? (Community discussion · Accessed 2026-09-30)

Identity and interactions remain unresolved. Salt color, a seller label or a certificate claim cannot identify an unknown analog. Original concerns include contamination, mg/mcg errors and enzyme-versus-inhibitor labeling. Long-term systemic methylation effects, cancer-risk implications, pregnancy, lactation and interactions with metabolic stacks remain uncertain; short animal tolerability does not settle them. Reddit: Looking for real-world experiences and data on 5-Amino-1MQ (Community discussion · Accessed 2026-09-30)

Full notes

What the different names mean

A shared enzyme target, several different molecules. NNMT uses nicotinamide and a methyl donor, SAM, to make 1-methylnicotinamide. Inhibitors interrupt that reaction. JBSNF-000088 is 6-methoxynicotinamide; JBSNF-000028 is a tricyclic molecule. JBSNF-000265, 7-amino-1MQ and 2,3-diamino-1MQ are additional research identities, not interchangeable versions of one capsule. Animal context Animal context Community
An inhibitor is different from an NAD precursor. NMN and NR supply precursors; NNMT inhibition is discussed as changing how nicotinamide is used. Neither makes an unidentified “NNMTi” powder equivalent to 5-Amino-1MQ. These are small molecules, despite their frequent appearance in peptide communities. Community

Why people are interested

Energy, training and body recomposition. Parent users seek easier fat loss while maintaining training. In the May thread, one person describes 1 mg SubQ alongside retatrutide for energy without caffeine-like jumpiness. That experience does not establish a JBSNF benefit or a measured increase in metabolic rate. Reddit r/BiohackingU
Little buzz and relatively unchanged appetite in original parent accounts. Those discussions contrast the parent with GLP-1 appetite suppression. Warmth or alertness also appears, but neither sensation measures fat oxidation or establishes how a different inhibitor feels. Community
Energy does not necessarily mean fat loss. Theappache10 described only a small energy benefit from injectable parent, without the hoped-for fat burning. Dull_Secretary_6734 felt energized after two weeks alongside retatrutide, but had not yet seen other benefits. Neither account isolates NNMT inhibition from the product or stack. Reddit r/BiohackingU

Doses people discuss

These are descriptions of labels, reports and competing charts, not instructions. 1 mg equals 1,000 mcg. Daily totals and amounts per capsule are different.

One blend label: 50 mg parent, 50 mg NMN, 5 mg JBSNF-000088 per capsule. An Evolutionary forum poster asks about this oral combination. Frequency and completed results are absent; the 5 mg component is not an established standalone human dose. Evolutionary.org
Parent oral reports: 50–150 mg total per day. Examples include 50 mg/day as two 25 mg doses, or 150 mg/day as 100 mg morning plus 50 mg midday. Separate original charts claim 5–25 mg/day, 100–300 mg/day or more, and mouse-derived 400–600 mg/day. These do not establish analog doses. Reddit r/ResearchCompounds Reddit r/PeptideForum Community
Injected parent reports differ by orders of magnitude. Theappache10 reports 500 mcg–1.5 mg beneath the skin, with frequency unstated. Another thread includes 1 mg SubQ, 5 mg/day split into two 2.5 mg injections, and claims favoring much higher amounts. The original 150–500 mcg/day SC band remains a separate chart, not an oral conversion. Reddit r/BiohackingU Reddit r/BiohackingU Community

Half-life

No measured human clock for the class in these discussions. One parent user invokes a short half-life to justify split SubQ doses; another explicitly borrows 38% oral bioavailability from rodents. Neither supplies human clearance measurements. Borrowed animal or parent assumptions cannot set JBSNF timing. Half-life measures elimination, not how long energy or fat loss lasts. Reddit r/BiohackingU Community

Onset: when a change is noticed

Parent impressions at 2–3 weeks, or no benefit. The oral log describes easier dieting at 2–3 weeks; Naven71 noticed nothing after 30 days. Neither establishes another inhibitor's onset. Reddit r/ResearchCompounds

Duration: how long effects last

A reliable single-dose benefit window is unknown. Letsgobeachfun felt nothing by a second parent dose while also using SS-31, tirzepatide and GLOW. An early null cannot measure how long one dose acts; persistence after stopping a named analog is unestablished here. Reddit r/BiohackingU Community

Cycles and breaks

Parent blocks: 4–6 weeks or 8–12 weeks. DiscreetAcct4 describes 4–6 weeks on, 2–4 off: injected parent:NADH at 5:4, about 15 mg parent per administration, frequency unstated. Original charts instead include 8–12 weeks and 4–6-week breaks. No validated analog cycle follows. Reddit r/ResearchCompounds Community

Adverse reports and unresolved risks

Parent symptoms include emotional dulling, anxiety and disrupted sleep. The oral log reports emotional dulling at week three; another thread reports anxiety and disturbed sleep. Original accounts also mention nausea, loose stools, headache and fatigue. None establishes a class adverse-effect rate. Reddit r/ResearchCompounds Reddit r/PeptideForum Community
Identity and interactions remain unresolved. Salt color, a seller label or a certificate claim cannot identify an unknown analog. Original concerns include contamination, mg/mcg errors and enzyme-versus-inhibitor labeling. Long-term systemic methylation effects, cancer-risk implications, pregnancy, lactation and interactions with metabolic stacks remain uncertain; short animal tolerability does not settle them. Community Reddit r/BiohackingU

What the community accounts add

A leaner appearance can outpace the scale, with imperfect attribution. Traditional-War985 reported four pounds lost and a two-percentage-point body-fat decrease during a five-week parent course. The scans were three months apart, covering more than the exposure period. Their liquid amounts were stated in mL without concentration, so an mg dose cannot be reconstructed. Reddit r/PeptideForum
No response is not automatically a dosing mistake. ReasonEffective7123 reported no results after two weeks at 50 mg and four at 100 mg. Replies blamed dose; that explanation remains unproven. Reddit r/PeptideForum
Improvement can coexist with burning. Zurbino described faster weight loss alongside burning with injected parent. A perceived benefit does not erase an adverse experience. Reddit r/ResearchCompounds
Stacks make the supposed “next-generation” advantage difficult to judge. Original discussion pairs parent NNMTi with semaglutide, tirzepatide, retatrutide, MOTS-c and NMN or NR, sometimes adding GH-axis compounds. NMN/NR amounts around 250–500 mg/day and late-in-a-cut sequencing belong to stack-blog claims. They do not demonstrate an analog interaction, synergy or superiority. Community
Research excitement is different from a completed analog diary. A MuscleChemistry post retells mouse results and mentions unspecified human anecdotes. It supplies no named alternate-inhibitor human log. The JBSNF blend question likewise remains a question; a laboratory name on a label is not proof of a better human outcome. MuscleChemistry Evolutionary.org

Separate animal and laboratory context

JBSNF-000088: mouse oral exposure, not the 5 mg blend label. Kannt's study used 50 mg/kg twice daily for roughly four weeks. Diet-induced-obese mice lost weight; genetic obesity models did not show the same weight result. Plasma MNA fell through four hours after a separate oral dose. That endpoint is target engagement, not human felt duration. Animal context
JBSNF-000028: mouse half-lives of 2.36 hours oral and 1.77 hours IV. Those measured means followed 10 mg/kg oral and 1 mg/kg IV. Its 50 mg/kg twice-daily efficacy design was separate. A screen found 90% MAO-A inhibition at 10 µM; this is molecule-specific laboratory activity, not a demonstrated human drug interaction. Animal context
Parent rat half-lives: 6.90 hours oral, 3.80 hours IV. Awosemo's assay study reported 38.4% oral bioavailability in rats. These are parent-compound animal values, distinct from SC anecdotes, the JBSNF molecules and any human capsule exposure. Animal context